The vaccine, which protects against the human papilloma virus, was first introduced in 2008 and was offered to girls aged 12 to 13.
"These results provide strong evidence of HPV vaccination working to prevent cervical cancer in real-world settings, as HPV infections - which are the cause of cervical cancer - and precancerous cervical lesions are significantly declining", study author and professor Marc Brisson of Université Laval in Quebec said in a statement to USA Today.
"Even though the vaccine has only been available in the United Kingdom for girls for nine years, it is very exciting that decreases in pre-cancerous lesions in the cervix and in genital warts have already been seen".
A vaccine against cervical and other cancers should be recommended for both men and women up to age 26, a US Government advisory panel decided last Wednesday. "Although it is very unlikely that your son or daughter is at risk of HPV infection at this age, it is recommended that they have the vaccine now because studies show that protection from the vaccine is better when it is given at an earlier age". For example, a middle-aged person re-entering the dating scene who had few previous sexual partners could become exposed to the virus for the first time, and might benefit from the vaccine. The study suggests substantial reductions in the number of cervical cancer case over the next decade.
This is why the team focused their research on rates of HPV infection aside from precancerous lesions and anal and genital warts, which are the side-effects of the virus. Researchers found that in countries where the vaccine had been distributed for more than five years, the rates of HPV infection decreased by 83 percent among teenage girls and 66 percent among young women. The HPV vaccine can also be given to women above the age of 25. However, in countries where it is also provided to young men and women over the age of 20, the effects of protection were higher and quicker.
The World Health Organization issued a call to action previous year to try to eradicate cervical cancer, one of the most common cancers among women around the world.
The HPV vaccine is mostly offered in higher income countries now, with mid to lower income countries not yet rolling it out fully to young men and women.